20-F: SL Science Completes Business Combination, Lists on Nasdaq

SL Science Holding Limited announced the successful completion of its business combination and commencement of trading on the Nasdaq under the symbol SLBT.

Summary

• SL Science Holding Limited (SLBT) has successfully completed its business combination with Horizon Space Acquisition II Corp. (HSPT) and SL Bio Ltd.
• The combined entity's ordinary shares began trading on the Nasdaq Stock Market on June 15, 2026, under the ticker symbol SLBT.
• The business combination involved a merger between Merger Sub I and HSPT, followed by a merger between Merger Sub II and SL Bio, with SL Bio becoming a subsidiary of SLBT.
• As a result of the business combination, HSPT shareholders and SL Bio shareholders received ordinary shares of SLBT.
• The company is focused on developing innovative cellular and gene therapies, specifically targeting cancer treatment with its Armed-T Therapy and Gamma Delta T (GDT) Cell Culture Technology.
• SL Science has also been developing exosome-based cosmetic and plant extract hair care products, with plans to gradually phase out these legacy businesses as its cell therapy pipeline matures.
• The company has entered into licensing agreements with CytoArm for CD-19 Armed-T Therapy and with JY BioMed for GDT Cell Therapy products.
• SL Science has not yet obtained FDA clearance or approval for any product candidates and is currently in pre-clinical stages for its CD-19 Armed-T Therapy and GDT Cell therapies.
• The company anticipates filing an IND for its CD-19 Armed-T products in Q1 2027 and for its GDT cell therapy products in Q3 2027.
• The company reported a net loss of $3,819,818 for the year ended December 31, 2025, compared to a net loss of $1,191,333 for the year ended December 31, 2024.
• Net revenue decreased by 35% from $3,363,603 in 2024 to $2,197,249 in 2025, primarily due to a shift in sales strategy for exosome concentrate products.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to the significant revenue decline, widening net loss, and the long, uncertain development timelines for its core cell therapy products, despite the positive milestone of completing the business combination and listing on Nasdaq.

Positives

• Successful completion of a business combination and listing on the Nasdaq under the ticker SLBT.
• Development of proprietary technologies in cellular and gene therapies, including Armed-T Therapy and Gamma Delta T (GDT) Cell Culture Technology.
• Strategic licensing agreements with CytoArm and JY BioMed to advance product development.
• Focus on significant unmet medical needs in cancer treatment, specifically pancreatic and brain cancers.
• Market potential in the growing global cancer therapeutics market, with specific targets in pancreatic and brain cancer treatment markets.
• Experienced leadership team with expertise in biotech and finance.
• Secured $7.8 million in gross proceeds from a PIPE financing at $10.00 per unit.

Negatives

• Significant net loss of $3,819,818 for the year ended December 31, 2025.
• Revenue decline of 35% in 2025 compared to 2024, attributed to a strategic shift in sales model.
• All product candidates are in pre-clinical stages; no FDA clearance or approval has been obtained.
• IND submission for key therapies is projected for Q1 2027 (Armed-T) and Q3 2027 (GDT cells), indicating a long development timeline.
• High operating expenses, with general and administrative expenses increasing by 123% in 2025 due to expansion of the senior management team.
• The company has a history of net losses and an accumulated deficit of $5,484,378 as of December 31, 2025.
• Reliance on licensing partners (CytoArm and JY BioMed) for technology and development.
• Potential for significant future capital expenditures for research, development, and production capacity.

Risks

• The company has not yet obtained FDA clearance or approval for any of its product candidates, and they are all in pre-clinical trials.
• The timeline for IND submission for CD-19 Armed-T products is Q1 2027, and for GDT cell therapy products is Q3 2027, indicating a long path to market.
• The company has incurred significant net losses and has an accumulated deficit, raising concerns about its ability to fund future operations.
• Future success is dependent on securing additional funding through equity or debt financing.
• The company faces intense competition from established pharmaceutical companies and other biotechnology firms in the cell therapy and oncology space.
• The company's legacy exosome cosmetic and plant supplement businesses may be phased out as cell therapy development progresses.
• The company's ability to commercialize its products depends on successful clinical trials and obtaining regulatory approvals.
• The company's reliance on licensing agreements with CytoArm and JY BioMed carries risks related to the terms of these agreements and the performance of the licensors.
• The company's business model is heavily reliant on the success of its R&D efforts and the ability to attract strategic partnerships.
• The company's financial performance is subject to the uncertainties inherent in the biotechnology industry, including clinical trial outcomes and regulatory hurdles.

Future Outlook

SL Bio's vision is to be a leading provider of innovative cellular therapies globally, focusing on transforming cancer treatment and regenerative medicine. The company plans to achieve this through product development, continuous improvement of R&D capabilities with partners, new product development, acquisitions, licensing, intellectual property application, and investing in R&D capabilities. The company also intends to increase the market value of its intellectual property portfolio to support global product licensing. The company expects to gradually phase out its legacy exosome cosmetic and plant supplement businesses.

Management Comments

• SL Science aims to create cellular therapies that have the potential to revolutionize the cell therapy and immuno-oncology sector.
• The company intends to position itself as a potential leader in the next-generation allogeneic cell therapy industry.
• SL Science is dedicated to the research and development of bispecific antibodies to enhance blood cancer treatment.
• The company's GDT cell therapy technology is focused on enhancing treatments for pancreatic and brain cancers.
• SL Science has not yet obtained FDA clearance or approval for any of its product candidates, nor has it completed Phase I, II, or III clinical trials, or submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).

Industry Context

StockSavvy.ai notes that SL Science is operating in the highly competitive and rapidly evolving biopharmaceutical sector, specifically focusing on cell and gene therapies for oncology. The company's strategy to leverage licensing agreements and partnerships with entities like CytoArm and JY BioMed is a common approach in this capital-intensive industry. The significant market potential for cancer therapeutics, particularly for pancreatic and brain cancers, provides a strong backdrop for SL Science's development efforts, but the long and uncertain path to FDA approval and commercialization remains a key challenge.

Comparison to Industry Standards

• Competitors in the GDT cell therapy space include Adicet Bio, Inc. (Nasdaq: ACET), IN8bio, Inc. (Nasdaq: INAB), GammaDelta Therapeutics (a Takeda company), and TC BioPharm, all of which are developing similar allogeneic or engineered T cell programs.
• In the CD-19 Armed-T therapy space, competitors like Novartis (Kymriah) and Gilead (Yescarta) offer CAR-T therapies, which, while successful, have limitations such as complex manufacturing, irreversible genetic modification, and potential toxicities like cytokine release syndrome and neurotoxicity.
• SL Science's exosome skincare products compete with brands like Purasomes by Dermoaroma, BIOREG EXOSOME + HA by My Skin Chemistry UK, and Medicube, which also utilize exosome-based formulations.
• The company's plant extract hair care products compete with brands like Nutrafol (Unilever) and The Ordinary, as well as drug-based treatments like minoxidil and finasteride.

Legal Proceedings

• The company is currently not a party to any material legal or administrative proceedings.
• The company may, from time to time in the future, be subject to various legal and administrative proceedings arising in the ordinary course of its business.

Related Party Transactions

• SL Bio paid $455,714 to JY BioMed (owned by CTO Dr. Shen) for research and development costs for GDT Cells Licenses during the year ended December 31, 2025.
• During the year ended December 31, 2024, SL Bio had transactions with SL Link (owned by director Mr. Wang) for operating leasing income ($167,795), general corporate and accounting services ($80,496), and research and development costs for CD-19 Patent transfer ($949,771).
• During the year ended December 31, 2024, SL Bio paid $964,823 to JY BioMed (owned by CTO Dr. Shen) for research and development costs for GDT Cells Licenses.
• Mr. Wang, Chairman and CEO, indirectly owns approximately 12.6% in CytoArm, a licensor of the CD-19 Armed-T technology.

Stakeholder Impact

• Shareholders: The successful business combination and Nasdaq listing provide a public market for shares, but the company's significant losses and long development timelines present substantial investment risk.
• Employees: The company is expanding its workforce, including hiring a Chief Medical Officer, to support clinical trial efforts, indicating potential job growth but also reliance on skilled personnel.
• Partners (CytoArm, JY BioMed): Milestone payments and royalties are contingent on the success of SL Science's product development and commercialization efforts.
• Creditors: The company's financial condition and need for future funding may impact its ability to meet debt obligations if additional capital is not secured.

Next Steps

• Address FDA comments regarding nonclinical, manufacturing, and release-testing packages for CD-19 Armed-T products.
• Conduct additional nonclinical studies and further develop manufacturing and release-testing methods for CD-19 Armed-T products.
• Request a pre-IND meeting with the FDA for CD-19 Armed-T products.
• File an IND application for CD-19 Armed-T products, currently anticipated in Q1 2027.
• Complete IND-enabling GLP toxicology studies for GDT cell therapy products.
• File an IND application for GDT cell therapy products, currently anticipated in Q3 2027.
• Proceed with Phase I clinical trials for both CD-19 Armed-T and GDT cell therapy products upon IND approval.
• Seek development and commercialization partnerships with global pharmaceutical companies following early clinical validation (e.g., late Phase I/early Phase II).
• Gradually phase out legacy exosome cosmetic and plant supplement businesses while fulfilling existing contractual obligations.

Key Dates

Recommendation

While the business combination and Nasdaq listing are positive steps, the company's significant net losses, revenue decline, and the long, uncertain path to FDA approval for its core cell therapy products warrant a cautious approach. The company is still in the early stages of development, and the substantial risks associated with clinical trials and regulatory approvals mean that investors should 'hold' and monitor progress closely rather than initiating new positions.

Keywords

SL Science Holding Limited, SLBT, Business Combination, Nasdaq, Cell Therapy, Gene Therapy, Armed-T Therapy, Gamma Delta T Cells, Oncology, Biotechnology, FDA Approval, IND Submission, Pre-clinical Trials, Exosome, Plant Extract